Secreted phospholipase PLA2G5 acts as a hemolytic factor in sepsis

Area of Science:

• Immunology
• Molecular Biology
• Pathophysiology

Background:

• Sepsis is a life-threatening condition with high mortality rates.
• Hemolysis is a known complication and predictor of mortality in sepsis.
• The molecular mechanisms driving sepsis-induced hemolysis are not fully understood.

Purpose of the Study:

• To investigate the role of secreted phospholipase PLA2G5 in sepsis-induced hemolysis.
• To explore PLA2G5 as a potential therapeutic target for sepsis.

Main Methods:

• Measured organism-wide gene expression changes during sepsis.
• Utilized genetic deletion of Pla2g5 and antibody neutralization in mouse models.
• Assessed splenic red pulp macrophage populations and iron homeostasis.
• Analyzed serum PLA2G5 levels in human sepsis patients.

Main Results:

• PLA2G5 was induced in colon cells during sepsis.
• Genetic deletion or antibody blockade of PLA2G5 conferred protection from lethal sepsis.
• PLA2G5 blockade improved iron homeostasis and splenic red blood cell regulation.
• Elevated serum PLA2G5 levels in human sepsis patients correlated with disease severity and mortality.

Conclusions:

• Sepsis induces PLA2G5, which acts as an intravascular hemolytic factor.
• PLA2G5 contributes to red blood cell destruction and mortality in sepsis.
• PLA2G5 is a potential biomarker and therapeutic target for sepsis.